If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A Spanish research group of the public health system has developed a preloaded injectable device for the treatment of cerebral edema in altitude sickness. A license agreement or an agreement for a public or private partnership for the further development of the patented technology is sought.
Cerebral edema is the accumulation of fluid in and resultant swelling of the brain that may be caused by lack of oxygen at high altitudes, trauma, a tumor or exposure to toxic substances.
A Spanish hospital research group has developed a pharmaceutical composition with high stability under extreme environmental conditions typical of a high altitude, for the treatment of cerebral edema in acute mountain sickness.
This pharmaceutical composition is presented in an injectable device preloaded whose form of administration may be intramuscular, intravenous or by subcutaneous injection and can be used therefore as an emergency treatment.
The research group is looking for the following collaboration:
-License agreement: framework of authorizing the interested parties to use the solution.
-Technical cooperation agreement: to collaborate with other research teams, companies or foundations.
- It reduces the absorption time at the systemic level and accelerates the therapeutic effect.
- It has greater ease of administration intramuscularly by combining in a single device all the active substances necessary for the immediate management of the acute stages of the disease.
- It has high stability under extreme weather conditions of high altitude for the treatment of cerebral edema in acute mountain sickness because the substances are structurally stable to this extreme conditions for at least 28 days.
- It allows faster administration and improvement in the treatment of acute cerebral edema of mountain allowing the survival of these athletes.
PCT patent application
The research group aims to formalize a technology transfer process with entities interested in the implementation of the solution, through a license agreement.
If there are some entities, such as R&D centres, technology centres or specialized companies, interested in collaborating and developing further aspects of the solution, a technical cooperation agreement could be envisaged.
The group already sell the technology in Spain and now they want to expand abroad